Please login to the form below

Not currently logged in
Email:
Password:

Celltrion

This page shows the latest Celltrion news and features for those working in and with pharma, biotech and healthcare.

Hardy returns to Genentech as CEO

Hardy returns to Genentech as CEO

In the US, the FDA has already approved three Herceptin copycats – Celltrion and Teva’s Herzuma, Samsung Bioepis’ Ontruzant and Myland’s Ogivri, however the companies will have to wait until

Latest news

More from news
Approximately 13 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    This has provided an opportunity for companies specialising in development of biosimilars to win deals from big companies, such as the $160m agreement between Teva and Celltrion in the US and

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation. Biosimilar rituximab and trastuzumab in phase III in North America.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Assets that Hospira acquired with Celltrion are essentially replicas of existing Pfizer programmes eg Herceptin and Rituxan and these will probably be divested.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Celltrion. South Korea. CT-P10. Clinical. FL: Phase III started in Dec 2011. ... 7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics